This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects.
The report enhances decision-making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MoAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Genital Herpes Overview
- Therapeutics Development
- Pipeline Products for Genital Herpes - Overview
- Pipeline Products for Genital Herpes - Comparative Analysis
- Genital Herpes - Therapeutics under Development by Companies
- Genital Herpes - Therapeutics under Investigation by Universities/Institutes
- Genital Herpes Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Genital Herpes - Products under Development by Companies
- Genital Herpes - Products under Investigation by Universities/Institutes
- Genital Herpes - Companies Involved in Therapeutics Development
- Admedus Ltd
- AiCuris GmbH & Co. KG
- Foamix Pharmaceuticals Ltd.
- Genocea Biosciences, Inc.
- GenVec, Inc.
- Immune Design Corp.
- Immunovaccine, Inc.
- Mymetics Corporation
- NanoBio Corporation
- NanoViricides, Inc.
- PaxVax, Inc.
- Profectus BioSciences, Inc.
- Sanofi Pasteur SA
- Shulov Innovative Science Ltd.
- Starpharma Holdings Limited
- Vaccibody AS
- Vaxart, Inc.
- Vical Incorporated
For more information visit http://www.researchandmarkets.com/research/s646vj/genital_herpes